Release Date: December 22, 2025
Expiration Date: December 22, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in acute lymphocytic leukemia (ALL). In this educational program, these experts discuss the integration of T-cell therapies, including CAR T-cell therapies, immunotherapies, and bispecific antibodies, as well as best practices for sequencing CD19-targeting therapies. By placing the data in a clinical context, oncology practitioners can assess and apply these findings to their clinical practice and ultimately improve care for their patients with ALL.
This educational activity is an archive of the live symposium held on December 18, 2025.
Target Audience
This educational activity is directed toward academic and community-based oncologists, advanced practice providers, oncology nurses, and other health care providers involved in the treatment of patients with ALL.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate recent clinical trial data on approved and emerging therapeutic strategies for acute lymphocytic leukemia (ALL), with a focus on advances in bispecific antibodies and CAR-T cell therapies
- Interpret the latest guidelines and evidence for biomarker-driven strategies to stratify risk and guide the use of bispecific and CAR-T cell therapies in patients with ALL
- Describe best practices for mitigating and managing treatment-related adverse events in patients with ALL
Claire Roddie, MD, PhD
Clinical Lead, CAR T
University College London (UCL) Hospitals
Associate Professor in Hematology
UCL Cancer Institute
London, England
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Autolus, BMS, Kite/Gilead, J+J
Elias Jabbour, MD
Professor, Department of Leukemia
The University of Texas
Anderson Cancer Center
Houston, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Amgen, Autolus, Kite Pharma, Novartis, Pfizer, Takeda and Ascentage Pharma; Grant/Research Funding: Amgen, Autolus, Novartis, Kite Pharma, Pfizer, Takeda and Ascentage Pharma
Hagop Kantarjian, MD
Professor and Chair
Samsung Distinguished University Chair in Cancer Medicine
Department of Leukemia Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, Ascentage Pharma, Ipsen Biopharmaceuticals, KAHR Medical, Novartis, Pfizer, Shenzhen TargetRx, Stemline Therapeutics, Takeda; Grant/Research Funding: AbbVie, Amgen, Ascentage Pharma, Bristol Myers Squibb, Daiichi-Sankyo, ImmunoGen, Novartis
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here